J. Flynn

发表

Flavopiridol (alvocidib) in chronic lymphocytic leukemia

Thomas S. Lin, M. Moran, B. Fischer, 2009 .

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

J. Byrd, K. Kolibaba, T. Kipps, 2016, Blood.

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

C. Hofmeister, E. Hade, G. Lozanski, 2015, Leukemia & lymphoma.

Absence of HLA-DR1 positivity in 2 familial cases of frontal fibrosing alopecia.

J. Flynn, Francisca Kartono, N. Dipaola, 2014, Journal of the American Academy of Dermatology.

Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL.

J. Byrd, N. Heerema, K. Blum, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib treatment improves T cell number and function in CLL patients

Jeffrey A Jones, M. Caligiuri, J. Byrd, 2017, The Journal of clinical investigation.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

J. Byrd, C. Hofmeister, F. Pichiorri, 2017, Leukemia & lymphoma.

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia

Jeffrey A Jones, M. Grever, J. Byrd, 2015, Leukemia.

Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.

Jeffrey A Jones, J. Byrd, N. Heerema, 2015, Clinical lymphoma, myeloma & leukemia.

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.

Jeffrey A Jones, M. Grever, J. Byrd, 2015, Blood.

Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma

Jeffrey A Jones, R. Baiocchi, K. Blum, 2013, Bone Marrow Transplantation.

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2012, Blood.

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Michael A. Freitas, Jeffrey A Jones, J. Byrd, 2012, Cancer cell.

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

Michael A. Freitas, Jeffrey A Jones, J. Byrd, 2011 .

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is Chemotherapy the Standard for Asymptomatic Androgen- Independent Prostate Cancer?

J. Byrd, J. Flynn, 2008 .

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Jeffrey A Jones, J. Byrd, R. Baiocchi, 2010 .

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non‐Hodgkin's lymphoma

Jeffrey A Jones, M. Grever, J. Byrd, 2014, American journal of hematology.

Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma

J. Byrd, J. Flynn, R. Howard, 2002, Cancer.

Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib resistant CLL confers BTK independency upon BCR activation

Jeffrey A Jones, J. Byrd, A. Johnson, 2015 .

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014, Blood.

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2015, American journal of hematology.

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.

Jeffrey A Jones, J. Byrd, A. Johnson, 2014, Leukemia research.

Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation

Jeffrey A Jones, M. Grever, J. Byrd, 2010, British journal of haematology.

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.

Jeffrey A Jones, M. Grever, J. Byrd, 2017, Blood advances.

Have we forgotten the purpose of phase III studies?

J. Byrd, J. Flynn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia

Jeffrey A Jones, J. Byrd, A. Johnson, 2017, Cancer medicine.

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

Jeffrey A Jones, J. Byrd, F. Awan, 2016, Leukemia.

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

Jeffrey A Jones, K. Williams, L. Andritsos, 2014, Leukemia.

Adolescent and young adult oncology, version 2.2014.

D. Wechsler, Dorothy Shead, R. Goldsby, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

J. Byrd, I. Flinn, R. Garzon, 2014 .

Campath-1H monoclonal antibody therapy

J. Byrd, J. Flynn, 2000, Current opinion in oncology.

Campath-1 H monoclonal antibody therapy

J. Byrd, J. Flynn, 2022 .

Title: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes Short Title: Ibrutinib is an immunomodulatory ITK inhibitor

Lisa L. Smith, M. Caligiuri, J. Byrd, 2016 .

Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM.

J. Byrd, J. Flynn, N. Muthusamy, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2013, Leukemia research.

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2012, Leukemia.

Adolescent and young adult oncology, version 2.2014.

D. Wechsler, Dorothy Shead, R. Goldsby, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Jeffrey A Jones, J. Byrd, N. Heerema, 2010 .

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.

Jeffrey A Jones, J. Byrd, A. Johnson, 2013, Blood.

Lymphoma in adolescents and young adults.

J. Flynn, S. Jaglowski, A. Termuhlen, 2009, Seminars in oncology.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

David Jarjoura, John R Desjarlais, Bo Yu, 2010, Blood.

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

M. Grever, N. Heerema, G. Lozanski, 2012, Leukemia.

response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014 .

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Jeffrey A Jones, J. Byrd, A. Johnson, 2015, Blood.

Complex karyotype predicts for inferior outcomes following reduced‐intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia

Jeffrey A Jones, M. Grever, J. Byrd, 2012, British journal of haematology.

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma

Jeffrey A Jones, J. Byrd, F. Awan, 2015, Leukemia & lymphoma.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2015, JAMA oncology.

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

J. Byrd, A. Johnson, J. Flynn, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease

Jeffrey A Jones, J. Byrd, N. Heerema, 2009, British journal of haematology.

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

Jeffrey A Jones, Emanuela M. Ghia, J. Byrd, 2015, Proceedings of the National Academy of Sciences.

The phosphatidylinositol 3-kinase-δ Inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Jeffrey A Jones, Weiqiang, J. Byrd, 2010 .

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Jeffrey A Jones, Lisa L. Smith, M. Caligiuri, 2013, Blood.

Adolescent and young adult oncology. Clinical practice guidelines in oncology.

D. Wechsler, Dorothy Shead, R. Goldsby, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

Jeffrey A Jones, J. Byrd, R. Baiocchi, 2015, British journal of haematology.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Jeffrey A Jones, J. Byrd, A. Johnson, 2011, Blood.

Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived.

J. Byrd, J. Flynn, J. Waselenko, 1999, Seminars in oncology.

Key points

Jeffrey A Jones, J. Byrd, A. Johnson, 2019, Copyright for Archivists and Records Managers.

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center

Jeffrey A Jones, M. Grever, J. Byrd, 2014, Leukemia.

BTK C 481 S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

M. Grever, J. Byrd, F. Awan, 2017 .

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia

Jeffrey A Jones, J. Byrd, L. J. Lee, 2014, Leukemia.

A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor

Jeffrey A Jones, J. Byrd, N. Heerema, 2018, British journal of haematology.

Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies

Jeffrey A Jones, J. Byrd, A. Johnson, 2013, Leukemia & lymphoma.

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

Jeffrey A Jones, M. Grever, J. Byrd, 2012, Haematologica.

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol

Jeffrey A Jones, M. Grever, J. Byrd, 2011, Leukemia.

Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Jeffrey A Jones, J. Byrd, N. Heerema, 2011, Cancer genetics.

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Jeffrey A Jones, M. Grever, J. Byrd, 2008 .

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2016 .

A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

Jeffrey A Jones, M. Grever, J. Byrd, 2012 .

Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.

Jeffrey A Jones, M. Grever, J. Byrd, 2014 .

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

Jeffrey A Jones, J. Byrd, J. Flynn, 2014, mAbs.

Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies

Jeffrey A Jones, J. Byrd, G. Lozanski, 2013, mAbs.

Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia

Jeffrey A Jones, J. Byrd, B. Andersen, 2016, Annals of Hematology.

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.

Jeffery A. Jones, J. Byrd, G. Lozanski, 2015, Blood.

A phase 1 / 1 b study of rituximab , bendamustine , and ibrutinib in patients with untreated and relapsed / refractory non-Hodgkin lymphoma

Jeffery A. Jones, J. Byrd, G. Lozanski, 2014 .

Jumping translocations, a novel finding in chronic lymphocytic leukaemia

Jeffrey A Jones, M. Grever, J. Byrd, 2015, British journal of haematology.

Complete response to induction therapy in patients with Myc‐positive and double‐hit non‐Hodgkin lymphoma is associated with prolonged progression‐free survival

Jeffrey A Jones, N. Heerema, G. Lozanski, 2014, Cancer.

Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.

J. Byrd, K. Kolibaba, T. Kipps, 2014 .

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma.

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib

Jeffrey A Jones, J. Byrd, F. Awan, 2014 .

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009 .

A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL.

J. Byrd, I. Flinn, J. Flynn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adolescent and Young Adult OncologyPractice Guidelines in Oncology

D. Wechsler, Dorothy Shead, R. Goldsby, 2012 .

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

Jeffrey A Jones, M. Grever, J. Byrd, 2013, American journal of hematology.

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Jeffrey A Jones, J. Byrd, F. Awan, 2015 .

Profound neurological injury in a patient with atypical hemolytic uremic syndrome

J. Flynn, S. Cataland, G. Salem, 2013, Annals of Hematology.

Second malignancies in B‐cell chronic lymphocytic leukaemia: possible association with human papilloma virus

J. Byrd, L. Andritsos, J. Flynn, 2010, British journal of haematology.

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Jeffrey A Jones, J. Byrd, A. Johnson, 2016, Leukemia & lymphoma.

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

M. Grever, J. Byrd, C. Hofmeister, 2012 .

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Jeffrey A Jones, Lisa L. Smith, M. Caligiuri, 2012 .

Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy

B. Ramaswamy, C. Shapiro, G. Phillips, 2013, Supportive Care in Cancer.

Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2008 .

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol.

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

LYMPHOID NEOPLASIA Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jeffrey A Jones, M. Caligiuri, A. Johnson, 2013 .

HLA-DR1 in familial frontal fibrosing alopecia.

J. Flynn, H. Wong, D. V. Chan, 2015, Journal of the American Academy of Dermatology.

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2015, American journal of hematology.

The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma

Jeffrey A Jones, R. Baiocchi, K. Blum, 2011 .

A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.

J. Byrd, I. Flinn, L. Andritsos, 2009 .

Complex karyotype predicts for inferior outcomes following reduced‐intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia

Jeffrey A Jones, M. Grever, J. Byrd, 2012, British journal of haematology.

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

Jeffrey A Jones, J. Byrd, J. Flynn, 2014, mAbs.

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

C. Hofmeister, E. Hade, G. Lozanski, 2015, Leukemia & lymphoma.

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2013, Leukemia research.